Clinical impact of volume of disease and time of metastatic disease presentation on patients receiving enzalutamide or abiraterone acetate plus prednisone as first-line therapy for metastatic castration-resistant prostate cancer
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1479-5876
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Clinical impact of volume of disease and time of metastatic disease presentation on patients receiving enzalutamide or abiraterone acetate plus prednisone as first-line therapy for metastatic castration-resistant prostate cancer ; volume:21 ; number:1 ; day:3 ; month:2 ; year:2023 ; pages:1-7 ; date:12.2023
Journal of translational medicine ; 21, Heft 1 (3.2.2023), 1-7, 12.2023
- Creator
-
Nuzzo, Pier Vitale
Pederzoli, Filippo
Saieva, Calogero
Zanardi, Elisa
Fotia, Giuseppe
Malgeri, Andrea
Rossetti, Sabrina
Valenca Bueno, Loana
Andrade, Livia Maria Q. S.
Patrikidou, Anna
Mestre, Ricardo Pereira
Modesti, Mikol
Pignata, Sandro
Procopio, Giuseppe
Fornarini, Giuseppe
De Giorgi, Ugo
Russo, Antonio
Francini, Edoardo
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s12967-022-03861-2
- URN
-
urn:nbn:de:101:1-2023040809082450423371
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:48 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Nuzzo, Pier Vitale
- Pederzoli, Filippo
- Saieva, Calogero
- Zanardi, Elisa
- Fotia, Giuseppe
- Malgeri, Andrea
- Rossetti, Sabrina
- Valenca Bueno, Loana
- Andrade, Livia Maria Q. S.
- Patrikidou, Anna
- Mestre, Ricardo Pereira
- Modesti, Mikol
- Pignata, Sandro
- Procopio, Giuseppe
- Fornarini, Giuseppe
- De Giorgi, Ugo
- Russo, Antonio
- Francini, Edoardo
- SpringerLink (Online service)
Other Objects (12)
Impact of time to metastatic disease onset and extent of disease volume across metastatic hormone-sensitive and castration-resistant prostate cancer
Healthcare Costs for Metastatic Castration-Resistant Prostate Cancer Patients Treated with Abiraterone or Enzalutamide
Enzalutamide in Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer: An Asian Multiregional, Randomized Study
Pharmacokinetic Aspects of the Two Novel Oral Drugs Used for Metastatic Castration-Resistant Prostate Cancer: Abiraterone Acetate and Enzalutamide
Comment on: “Enzalutamide: A Step Towards Pharmacokinetic-Based Dosing in Men with Metastatic Castration-Resistant Prostate Cancer”
Survival by race in men with chemotherapy-naive enzalutamide- or abiraterone-treated metastatic castration-resistant prostate cancer
Long-Term Efficacy and Safety of Enzalutamide Monotherapy in Elderly Patients with Metastatic Castration-Resistant Prostate Cancer: A Case Report
Pediatric Metastatic Crohn's Disease
Matching-Adjusted Indirect Comparison of the Efficacy of Apalutamide and Enzalutamide with ADT in the Treatment of Non-Metastatic Castration-Resistant Prostate Cancer
A short account of metastatic bone disease
The molecular biology of peritoneal metastatic disease
Apalutamide, enzalutamide, and darolutamide for non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis
Impact of time to metastatic disease onset and extent of disease volume across metastatic hormone-sensitive and castration-resistant prostate cancer
Healthcare Costs for Metastatic Castration-Resistant Prostate Cancer Patients Treated with Abiraterone or Enzalutamide
Enzalutamide in Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer: An Asian Multiregional, Randomized Study
Pharmacokinetic Aspects of the Two Novel Oral Drugs Used for Metastatic Castration-Resistant Prostate Cancer: Abiraterone Acetate and Enzalutamide
Comment on: “Enzalutamide: A Step Towards Pharmacokinetic-Based Dosing in Men with Metastatic Castration-Resistant Prostate Cancer”
Survival by race in men with chemotherapy-naive enzalutamide- or abiraterone-treated metastatic castration-resistant prostate cancer
Long-Term Efficacy and Safety of Enzalutamide Monotherapy in Elderly Patients with Metastatic Castration-Resistant Prostate Cancer: A Case Report
Pediatric Metastatic Crohn's Disease
Matching-Adjusted Indirect Comparison of the Efficacy of Apalutamide and Enzalutamide with ADT in the Treatment of Non-Metastatic Castration-Resistant Prostate Cancer
A short account of metastatic bone disease
The molecular biology of peritoneal metastatic disease
Apalutamide, enzalutamide, and darolutamide for non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis
Impact of time to metastatic disease onset and extent of disease volume across metastatic hormone-sensitive and castration-resistant prostate cancer
Healthcare Costs for Metastatic Castration-Resistant Prostate Cancer Patients Treated with Abiraterone or Enzalutamide
Enzalutamide in Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer: An Asian Multiregional, Randomized Study
Pharmacokinetic Aspects of the Two Novel Oral Drugs Used for Metastatic Castration-Resistant Prostate Cancer: Abiraterone Acetate and Enzalutamide
Comment on: “Enzalutamide: A Step Towards Pharmacokinetic-Based Dosing in Men with Metastatic Castration-Resistant Prostate Cancer”
Survival by race in men with chemotherapy-naive enzalutamide- or abiraterone-treated metastatic castration-resistant prostate cancer
Long-Term Efficacy and Safety of Enzalutamide Monotherapy in Elderly Patients with Metastatic Castration-Resistant Prostate Cancer: A Case Report
Pediatric Metastatic Crohn's Disease
Matching-Adjusted Indirect Comparison of the Efficacy of Apalutamide and Enzalutamide with ADT in the Treatment of Non-Metastatic Castration-Resistant Prostate Cancer
A short account of metastatic bone disease
The molecular biology of peritoneal metastatic disease